secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001564590-22-036367
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana Biotechnology reports Q3 net loss $85.1M; cash $511.6M; pipeline IND timeline updates
--------------------------------------------------------------------------------

- Net loss of $85.1M ($0.45 per share) vs $83.3M ($0.46 per share) in Q3 2021; cash, cash equivalents and marketable securities $511.6M at Sep 30, 2022.
- Cash runway expected into 2025; operating cash burn $219.8M for nine months ended Sep 30, 2022.
- SC291 (allogeneic CAR T) IND filing on track for 2022 with clinical data expected in 2023.
- SG295 (in vivo CAR T) IND filing delayed to 2023 to incorporate second-generation process with 50X potency improvement.
- SC276 IND on track for 2023; SC451 (type 1 diabetes cell therapy) IND expected in 2024 with data in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000156459022036367/0001564590-22-036367-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000156459022036367/sana-8k_20221102.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-036367

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer